Gilead Reveals Leadership Transition As Milligan Takes CEO Role
This article was originally published in Scrip
Executive Summary
Gilead Sciences Inc. faced a lot of bad news related to its hepatitis C drugs during the last week of January, so there might have been a better time to announce a changing of the guard in the company's C-suite, no matter how much shareholders anticipated the succession plan.
You may also be interested in...
Milligan’s Retirement Means New CEO For New Gilead
While Milligan’s year-end departure topped the news, Gilead posted solid sales growth for Yescarta, got the HIV franchise back to growth and saw HCV’s decline largely stabilize. CSO McHutchison, meanwhile, predicted that selonsertib could be first to market in NASH.
Inexperienced Biotech CEOs Impact Investor Confidence – Analyst Research
Median tenure of large cap US biotech CEOs has decreased from 11 years in 2007 to one year in 2017, Leerink analyst Geoffrey Porges determined in an analysis of seven biotechs over 15 years.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.